Unapproved Weight-Loss Drug Retatrutide Goes Viral on Social Media, Raising Concerns
A new weight-loss drug, Tirzepatide (also known as Retatrutide), is causing a stir on social media platforms like TikTok and Instagram, despite not being approved for human use yet. Developed by Eisai Co., Ltd., this 'triple-threat' drug targets three hormones to aid weight loss. However, concerns are rising due to influencers promoting fake versions online.
Tirzepatide is currently in its third phase of development and has not received the green light from any regulatory body. It is expected to seek FDA approval in the US by mid-to-late 2026, with a potential worldwide launch in 2027. The drug works by targeting GLP-1, GIP, and glucagon receptors, making it a unique approach to weight loss.
Social media platforms are flooded with videos promoting Tirzepatide, but not all of them are legitimate. Influencers are peddling fake versions of the drug, posing a risk to those who might take these counterfeit substances. In response, TikTok and Instagram have been removing such videos to prevent harm to users.
Once approved, Tirzepatide's availability on the NHS is expected to be strictly controlled. The criteria to qualify for the drug are likely to be very stringent. Meanwhile, the pharmaceutical company behind Tirzepatide, Eisai Co., Ltd., continues to work towards its approval and launch, aiming to provide a new option for weight loss in the future.
